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Structural characterization of glutamate cysteine ligase (GCL),
the enzyme that catalyzes the initial, rate-limiting step in gluta-
thione biosynthesis, has revealed many of the molecular details
of substrate recognition. To further delineate the mechanistic
details of this critical enzyme, we have determined the struc-
tures of two inhibited forms of Saccharomyces cerevisiae GCL
(ScGCL), which shares significant sequence identity with the
human enzyme. In vivo, GCL activity is feedback regulated by
glutathione. Examinationof the structure of ScGCL-glutathione
complex (2.5 Å; R  19.9%, Rfree  25.1%) indicates that the
inhibitor occupies both the glutamate- and the presumed cys-
teine-binding site and disrupts the previously observed Mg2
coordination in the ATP-binding site. L-Buthionine-S-sulfoxi-
mine (BSO) is a mechanism-based inhibitor of GCL and has
been used extensively to deplete glutathione in cell culture
and in vivo model systems. Inspection of the ScGCL-BSO
structure (2.2 Å; R  18.1%, Rfree  23.9%) confirms that BSO
is phosphorylated on the sulfoximine nitrogen to generate
the inhibitory species and reveals contacts that likely contrib-
ute to transition state stabilization. Overall, these structures
advance our understanding of the molecular regulation of
this critical enzyme and provide additional details of the cata-
lytic mechanism of the enzyme.
Glutamate cysteine ligase (GCL)2 catalyzes the initial and
rate-limiting step of glutathione biosynthesis (1, 2). The ATP-
dependent mechanism proceeds via a -glutamylphosphate
intermediate (2–4), with a subsequent nucleophilic attack by
the-amino group of L-cysteine to produce -glutamylcysteine
(1, 2). There are three distinct families of GCL enzymes: -pro-
teobacteria (Group 1), nonplant eukaryotes (Group 2), and
-proteobacteria and plants (Group 3) (5). Despite low se-
quence conservation between these groups (typically 10%
sequence identity), all of the GCL appear to use this general
catalytic mechanism. The resulting -glutamylcysteine is cou-
pled to L-glycine by glutathione synthetase (1) in an analogous
reaction to generate reduced GSH, an abundant cellular reduc-
ing agent.
GCL activity is tightly modulated by free L-cysteine availabil-
ity (6), transcriptional regulation (7), and post-translational
modifications (8). In addition, GCL is feedback regulated by the
end product, glutathione (9). Glutathione inhibits GCL com-
petitively with respect to L-glutamate, suggesting that the two
binding sites are coincident (9). In heterodimeric GCL, such as
the Drosophila, rat, and human enzymes, binding of the modi-
fier subunit relieves feedback inhibition both by increasing the
Ki for glutathione anddecreasing theKm for glutamate (10–13).
Further studies with glutathione analogues such as ophthalmic
acid, S-methylglutathione, and GSSG have demonstrated that
the free thiol group of glutathione is necessary for maximal
inhibition (1, 9). However, the precise mode of glutathione
binding has not been described.
The central role of GCL in glutathione homeostasis makes
it an attractive target for drug design. Increased glutamate
cysteine ligase catalytic subunit mRNA levels and GCL activ-
ity have been frequently observed in cells derived from human
tumors resistant to chemotherapeutic agents (14–16). In-
creased production of glutathione likely protects against reac-
tive oxygen and nitrogen species (17, 18) and facilitates detox-
ification of electrophilic xenobiotics by the glutathione
S-transferases (19). Drug resistance in tumors can be overcome
by the administration of L-buthionine-S,R-sulfoximine (BSO)
(20), which inhibits GCL and subsequently depletes GSH, thus
sensitizing the cancer cells to radiation treatment and chemo-
therapy. Administration of BSOhas also been shown to prolong
the survival of mice infected with the parasite Trypanosoma
brucei (21), the causative agent of African sleeping sickness.
Similarly, BSO-mediated depletion of glutathione inhibits the
development Plasmodium falciparum in red blood cells (22).
BSO presumably binds as an L-glutamate analogue with its
S-butyl group extending into the L-cysteine-binding site (23).
Subsequent ATP-dependent phosphorylation of the sulfoxi-
mine nitrogen by GCL leads to the formation of a tightly bound
transition state analogue (20, 23).
Recently, we reported the crystal structure of Saccharomyces
cerevisiae GCL (ScGCL) in complex with L-glutamate, Mg2,
and ADP (24). As the first structure of a Group 2 glutamate
cysteine ligase, examination of the model provided important
molecular details of substrate recognition and led to the iden-
tification of key catalytic residues. In the current study, we have
determined the crystal structures of two inhibited forms of the
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enzyme. The structure of ScGCL in complex with glutathione
reveals the molecular details of feedback inhibition, whereas
the ScGCL-BSO complex structure details the mechanism of
BSO inhibition. Examination of the available ScGCL structures
provides considerable insight in the catalytic mechanism of the
enzyme and suggests approaches by whichGCL inhibitors with
greater selectivity may be attainable.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification—ScGCL was expressed
in Escherichia coli RosettaTM2(DE3) pLysS cells (Novagen) and
purified to homogeneity as described previously (24). Briefly,
soluble cell lysates were cleared of debris by centrifugation and
ScGCL isolated by affinity chromatography using a HisTrap
Chelating HP Column (GE Healthcare). The protein was further
purified by size exclusion chromatography using a Sephacryl 200
gel filtration column. Purified ScGCL was dialyzed against 20
mM Tris-HCl, pH 7.4, 2 mM dithiothreitol, concentrated (Ami-
con stirred cell 8050, 10-kDa cut-off), flash-frozen in liquid
nitrogen, and stored at 80 °C. Point mutations were intro-
duced at residue Cys266 (C266S and C266A) by using the
QuikChange site-directed mutagenesis kit (Stratagene) follow-
ing themanufacturer’s protocol. All of the constructs were ver-
ified by sequencing at the University of Nebraska Genomics
Facility (Lincoln, NE).
Kinetic Assays—Enzymatic activity was measured using an
indirect assay that couples ADP production to NADH oxida-
tion, which was monitored at 340 nm (11). The reaction mix-
ture contained 20 mM MgCl2, 5 mM phosphoenolpyruvic acid,
0.2 mM NADH, and 4 units each of pyruvate kinase and lactate
dehydrogenase in 1 ml of buffer (100 mM Tris, pH 8.0, 150 mM
KCl). The reaction was initiated by the addition of ScGCL. To
determine the apparent Km values, two of the three substrates
were added to the reaction at a saturating concentration (20mM
L-glutamate, 10 mM L-cysteine, 5 mM ATP), whereas the third
was varied. At high concentrations of cysteine or ATP, sub-
strate inhibition was observed.
To examine the mode of inhibition of glutathione, the rates
for the enzyme-catalyzed reaction as a function of glutamate
concentration were determined in the presence of fixed con-
centrations of glutathione (0, 2.5, and 5.0mM). A general mixed
model of inhibition was initially selected in Prism (Graph Pad
Software) to describe the dependence of rate versus substrate
concentration. This global analysis indicated that glutathione
was a competitive inhibitor with respect to glutamate. Follow-
ing this preliminary analysis, the datawere reanalyzed designat-
ing competitive inhibition (supplemental Fig. S1). For inactiva-
tion studies, ScGCL (1.75 M) was incubated with BSO (Sigma)
in 100 mM Tris, pH 8.0, containing 150 mM KCl, 20 mMMgCl2,
and 5mMATP at 4 °C (20, 25). At the indicated time, an aliquot
was removed, and enzymatic activity was measured at saturat-
ing substrate concentrations using the coupled assay system.
Representative data from three or more determinations are
plotted as a function of time with the experimental errors indi-
cated. A single-order decay was used to describe the data using
the program Prism (Graph Pad Software).
Crystallization, Data Collection, Structure Determination,
and Refinement—Concentrated ScGCL (7 mg/ml) was crystal-
lized in the presence of either 5mM reduced glutathione and 20
mM MgCl2 or 1 mM BSO, 5 mM ATP, and 20 mM MgCl2. Crys-
tals were grown at 18 °C out of a solution of 12% (w/v) polyeth-
ylene glycol 400, 100 mM MES, pH 6.8, with the dimensions
0.15  0.15  0.15 mm, as described previously (24). Prior to
data collection, the crystals were soaked in a stabilizing solution
containing 30% polyethylene glycol 400 and the appropriate
ligands and then vitrified in liquid nitrogen (26). Diffraction
data for the ScGCL-glutathione complex were collected using
radiation produced by a RigakuMicroMax-007 x-ray generator
fitted with confocal blue optics and an R-axis IV image plate
system (  1.54 Å; 100 K). For the ScGCL-BSO complex, dif-
fraction data (  0.9 Å; 100 K) were collected on Beamline
14-BM-C of BioCARS at Argonne National Laboratory Ad-
vanced Photon Source. All of the data were processed with the
HKL2000 software package (27). The structures of the ScGCL
complexes were determined by molecular replacement using
the PHENIX software suite (28) with the previously determined
ScGCL structure (Protein Data Bank code 3IG5) as the search
model. Iterative rounds of model building and refinement were
carried out using Coot (29) and Refmac5 (30), respectively. As
the protein models neared completion, water molecules obey-
ing proper hydrogen-bonding constraints with electron density
greater than 1.0  on a 2Fo  Fc map and 4.0  on an Fo  Fc
map were also included in the final structure. Model geometry
was monitored usingMOLPROBITY (31), and the figures were
produced using Chimera (32).
RESULTS AND DISCUSSION
Kinetic Characterization of ScGCL—Previously reported
structural and biochemical data indicate that ScGCL likely
functions as amonomer both in vitro and in vivo (24). To inves-
tigate its kinetic parameters, ScGCL was purified to homoge-
neity, and enzymatic activity was assessed using a coupled
enzyme system that monitors the production of ADP (11).
Apparent kinetic constants for the enzyme-catalyzed forma-
tion of -glutamylcysteine were determined (Table 1) and are
comparable with those reported for other eukaryotic GCL (1,
11–13, 33). Inhibition by glutathione, a feedback inhibitor of
ScGCL, was also examined. Glutathione is a competitive inhib-
itor with respect to the glutamate substrate (supplemental
Fig. S1), with an apparentKi(GSH) of 2.12 0.13mM, similar to
other Group 2 GCL holoenzymes (11–13, 33).
BSO is one of the most commonly used pharmacological
inhibitors of glutathione biosynthesis, and its efficacy with
respect to inhibition of ScGCL was examined (Fig. 1). A time-
dependent loss of enzymatic activity was observed in the pres-
ence of Mg2 and ATP at each of the BSO concentrations
TABLE 1
Apparent kinetic constants for wild-type ScGCL
Km Vmax Ki
mM mol min1 mg1 mM
L-Glutamate 1.21  0.05 10.7  0.17
L-Cysteine 0.17  0.01 10.9  0.19
ATP 0.08  0.01 16.1  0.56
GSH 12.0  0.18 2.12  0.13
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tested (5 M to 50 M). A near linear dependence on the inac-
tivation rate as a function of BSO concentration was observed
(data not shown). At 50 M BSO, ScGCL activity was reduced
nearly 10-fold in5min. Unfortunately, reliable rate measure-
ments above this concentration of BSO could not be made
because of the limitations of the assay. Nonetheless, BSO is
clearly a potent inhibitor of ScGCL. Previous studies of related
GCL indicated that L-buthionine-S-sulfoximine is the relevant
stereoisomer and that its enzymatic phosphorylation generates
a high affinity transition state analogue (23, 34). As discussed
below, the ScGCL-BSO structure supports these findings.
Overall Structures of ScGCL-Glutathione and ScGCL-BSO
Complexes—The structures of ScGCL in complex with either
glutathione or BSOwere determined bymolecular replacement
using the apo form of ScGCL as a probe (24). In the ScGCL-
glutathione complex, reduced glutathione was readily modeled
into the strong positive density observed within the enzyme
active site (supplemental Fig. S2). The glutamate portion of
glutathione is located at the base of the active site funnel (Fig.
2A). The cysteine moiety occupies a relatively hydrophobic
binding pocket, whereas the terminal glycine is near the outer
edge of the active site and is solvent-exposed. In the ScGCL-
BSO complex, the electron density supports the modeling of
phosphorylated BSO,ADP, and threeMg2 ions (supplemental
Fig. S3). The adenine ring of ADP is located at the lower lip of
the active site cavity and is solvent-exposed (Fig. 2B). The phos-
phorylated BSO occupies a site comparable but distinct from
the glutathione-binding site, as discussed below. The overall
ScGCL-glutathione and ScGCL-BSO structures are very simi-
lar to that of ScGCL in complex with glutamate andMg2 with
an root mean square deviation for C  0.2 Å (24). Refine-
ment statistics for the final ScGCL-glutathione and ScGCL-
BSO models are provided in Table 2. The refined ScGCL-glu-
FIGURE 2. Ribbon representations of the crystal structures of ScGCL in com-
plex with inhibitors. An ScGCL monomer is contained in the asymmetric unit,
and the N- and C-terminal residues are indicated. -Strands are colored in yellow,
and -helices are depicted in green. A, bound GSH is shown in space filling repre-
sentation with carbon atoms colored in gray, oxygen atoms are in red, sulfur
atoms are in yellow, and nitrogen atoms are in blue. The glutathione-binding site
overlaps the glutamate binding site within the active site funnel. B, ADP and the
transition state analogue, phosphorylated BSO (BSO-P), are shown in space filling
representation. Phosphorus and magnesium atoms are colored in orange and
purple, respectively, with the remaining atoms colored as in A.
TABLE 2
Data collection and refinement statistics
The values in parentheses are for the highest resolution shell.
ScGCL-GSH ScGCL-BSO
Data collection statistics
Protein Data Bank accession
code
3LVW 3LVV
Wavelength 1.54 Å 0.90 Å
Temperature (K) 100 100
Space group P43212 P43212
Cell dimensions (Å) 118.1, 118.1, 165.8 117.9, 117.9, 165.6
Resolution, Å 20.0-2.50 50.0-2.20
Rmerge (%) 10.1 (53.3) 5.7 (50.3)
Mean I/I 9.7 (3.0) 25.4 (2.8)
Completeness (%) 97.1 (96.1) 100.0 (100.0)
Average redundancy 8.77 (8.94) 18.7 (7.0)
Refinement statistics
Resolution, Å 20.0-2.5 (2.56-2.50) 50.0-2.20 (2.25-2.20)
Number of reflections 40,046 59,891
Rwork/Rfree (%) 19.9/25.1 (29.0/36.5) 18.1/23.9 (26.1/31.4)
Number of atoms 5702 5811
Protein 5476 5476
Ligand 50 58
Water 176 277
Average B-factors (Å2)
Protein 46.2 37.7
Ligand 56.9 33.8
Water 43.3 38.8
Root mean square deviations
from ideal
Bond lengths (Å) 0.02 0.02
Bond angles (°) 1.92 1.88
Ramachandran statistics
Favored (%) 95.4 96.9
Allowed (%) 99.7 99.7
FIGURE 1. Time-dependent inactivation of ScGCL by the inhibitor BSO.
ScGCL was incubated with a given concentration of BSO in the presence of
Mg2 and ATP at pH 8.0 and 4 °C. Relative enzymatic activity was monitored
as a function of time. The activity measurements were made in triplicate, and
the data for a given BSO concentration fit to a single exponential decay. The
curves are shown for the control (filled circles) and six experimental BSO con-
centrations (5 M, filled squares; 7.5 M, filled triangle; 10 M, filled inverted
triangle; 15 M, filled diamonds; 20 M, open circles; 50 M, open squares).
S. cerevisiae Glutamate Cysteine Ligase Inhibition
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tathione and ScGCL-BSO structures each have 99.7% of its
residues in the allowed regions of the Ramachandran plot.
The Glutathione-binding Site Is Coincident with the Gluta-
mate- andCysteine-binding Sites—As indicated above, reduced
glutathione is a competitive inhibitor of ScGCL with respect to
glutamate and a physiologically relevant feedback inhibitor of
the enzyme (9). The -carboxylate of the glutamyl moiety of
glutathione is positioned by hydrogen bonds with the side
chains of Tyr362 and Arg313 as well as with an ordered water
molecule (Fig. 3) that in turn forms a hydrogen bond with the
backbone carbonyl of Arg472 (not shown). Cys266 is also posi-
tioned above the plane of the carboxylate and may help orient
the bound inhibitor. The glutamyl -amino group is within
hydrogen bond distance of the backbone carbonyl of Cys264, the
-carboxylate of Glu52, and an ordered water molecule. The
cysteinyl -amino and -carbonyl groups are within hydrogen
bond distance of the -carboxylate of Glu96 and the indole
nitrogen of Trp445, respectively. An ordered water molecule
can also form a hydrogen bond with the cysteinyl -carbonyl
group. The side chain of Arg196 is positioned to interact favor-
ably with the terminal carboxylate of GSH, but the glycine por-
tion of glutathione is poorly defined relative to the rest of the
inhibitor.
As compared with the previously described ScGCL/Glu/
Mg2 structure, there are several notable differences in the
placement of the -glutamyl moiety of glutathione relative to
the bound glutamate substrate. In
the ScGCL/Glu/Mg2 structure, the
-carboxylate of the glutamate sub-
strate occupies one of the coordina-
tion sites of the bound M1 Mg2
(24). However, in the ScGCL-gluta-
thione structure, the -carboxylate
has been assimilated into the -glu-
tamyl peptide bond and can no lon-
ger promote Mg2 binding. Glu52
and Glu96, which also coordinate the
Mg2, maintain comparable posi-
tions in both structures, but Glu103
has shifted away from the M1 bind-
ing site (not shown). Loss of the M1
binding site causes the -glutamyl
portion of glutathione to be shifted
0.3 Å out from the base of the
active site, limiting interactions
between its -carboxylate and the
side chain of Arg313. In addition, the
M2 andM3binding sites are not sig-
nificantly occupied in the absence of
ATP or ADP.
An intriguing feature of the -glutamyl-binding pocket is the
conserved cysteine residue, Cys266, which is in close proximity
to the -carboxylate of glutamate. Previously, mutation of the
equivalent cysteine residue in T. brucei GCL to an alanine had
little effect on the specific activity or the substrate binding affin-
ity of the enzyme (35). In ScGCL, substitution of this residue
with either a serine (C266S) or an alanine residue (C266A) had
a modest but reproducible effect on glutamate and glutathione
binding (Table 3). For bothmutants, the apparentKm(Glu) and
the apparent Ki(GSH) increased 2-fold relative to the wild-
type enzyme. Studies to examine the impact of these mutations
on overall glutathione production in S. cerevisiae are ongoing.
Molecular Details of the L-Buthionine-S-sulfoximine-binding
Site—In addition to glutathione, all three families of GCL can
be inhibited by S-alkyl-L-homocysteine sulfoximines (36). As
discussed above, BSO is a potentmechanism-based inhibitor of
ScGCL. The enzyme catalyzes the ATP-dependent phosphor-
ylation of BSO to form BSO phosphate and ADP, which mimic
the transition state. Phosphorylated BSO binds tightly and dis-
sociates very slowly (20, 37), making this compound pharma-
cologically important for development of treatments against
cancer and certain parasites (21, 22, 38).
Phosphorylated BSO occupies the L-glutamate and the pre-
sumed L-cysteine-binding sites of ScGCL (Fig. 4A). The -car-
boxylate and -amino groups of BSO are virtually superimpos-
able on the comparable functional groups of the glutamate
substrate (not shown). BSO is phosphorylated on the sulfoxi-
mine nitrogen, and the S-butyl group of BSOmimics L-cysteine,
occupying a relatively hydrophobic pocket within the
enzyme active site. Arg472 is within hydrogen bond distance
of the sulfoximine oxygen and an oxygen of the newly added
phosphate group and likely stabilizes the transition state. In
support of a direct role in catalysis, mutation of the equiva-
lent arginine, Arg491 in T. brucei GCL, decreased enzymatic
FIGURE 3. Glutathione occupies the glutamate and presumed cysteine-binding sites of ScGCL. In the
stereodiagram, bound glutathione is shown in ball and stick representation, and pertinent active site residues
are shown in stick representation. The atoms are colored as in Fig. 2, with the exception of ScGCL carbon atoms,
which are colored green. Potential hydrogen bonds were identified in Chimera and are represented as solid
black lines.
TABLE 3
Apparent kinetic constants for C266S and C266A ScGCL
Km L-Glu Vmax V/K Ki glutathione
mM mol min1 mg1 mM
ScGCL 1.21  0.05 10.7  0.17 8.8 2.12  0.13
C266S 2.15  0.07 7.58  0.07 3.5 3.91  0.25
C266A 1.93  0.07 9.22  0.09 4.8 4.70  0.35
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activity by 70-fold (39). Phosphory-
lation by ATP and subsequent tight
inhibitor-enzyme interaction is de-
pendent on the metal ion binding
(1). The precise locations of the
three metal-binding sites are dis-
cussed below.
The crystal structures ofE. coli (40)
andBrassica juncea (41)GCL incom-
plex with alkyl sulfoximine inhibitors
have also been reported. Comparison
with the ScGCL-BSO complex re-
veals a dramatic conservation of ac-
tive site functionality across bacteria,
plants, and nonplant eukaryotes. In
these three structures, the -glu-
tamyl-binding sites are superimpos-
able, with the -carboxylate adja-
cent to a conserved arginine residue
(Arg313 in ScGCL) and the -amino
group within hydrogen bond dis-
tance of a bound water, the back-
bone carbonyl of residue 264, and
the carboxylate of Glu52 (Fig. 4A).
The proposed catalytic arginine res-
idue, Arg472 in ScGCL, is also con-
served and suggests that all three
enzymes function using a similar
mechanism.
Description of the ADP-binding
Site of ScGCL—Previously, we de-
scribed the structure of ScGCL in
complex with glutamate, ADP, and
Mg2 to 2.7 Å resolution (24). The
current ScGCL-BSO complex struc-
ture has been refined to significantly
higher resolution (2.2 Å) and pro-
vides additional details regarding
ADP binding (Fig. 4B). As described
previously, the 2 and 3 hydroxyls
of the ribose are involved in an
extended hydrogen bond network.
The oxygen of the furanose ring
forms a hydrogen bond with an
ordered water molecule that is posi-
tioned by the side chain of Arg468.
Substitution of the equivalent resi-
due in T. brucei GCL, Arg487, with
an alanine increases theKm(ATP)	
15-fold (39). The C6 amino group
and N7 nitrogen of the adenine ring
are within hydrogen bond distance of
the side chain of Gln272 and an
ordered water molecule, respectively.
Through bridging water molecules,
Thr270, Arg449, and Lys451 interact
with the pyrophosphate group of
ADP, and these residues are likely
FIGURE 4. Analysis of the x-ray structure of the ScGCL-BSO complex reveals details of catalysis. In the
stereodiagrams, bound ligands are shown in ball and stick representation, and pertinent active site residues
are shown in stick representation. Atoms are colored as in Fig. 2, with potential hydrogen bonds represented as
solid black lines. A, phosphorylated BSO mimics the transition state. The sulfoximine nitrogen is phosphorylated
and is within hydrogen bond distance of Arg472, which may facilitate catalysis by stabilizing the transition state.
B, additional details of the ADP binding site. Examination of a previously reported ScGCL structure led to the
identification of several protein/ligand interactions (24). The 2.2 Å resolution structure of the BSO-inhibited
enzyme reveals additional contributions to ADP binding. Most notably, the imidazole ring of His94 is in close
proximity to the -phosphate, and the side chain of Arg468 is within hydrogen bond distance of an ordered
water molecule that helps position the ribose ring of ADP. C, stereodiagram of Mg2-binding sites in the
refined model of ScGCL in complex with phosphorylated BSO (BSO-P) and ADP. In the stereodiagram, bound
ADP and phosphorylated BSO are shown, with potential hydrogen bonds between a catalytic arginine residue,
Arg472, and phosphorylated BSO represented as solid black lines. Three Mg2 ions, designated as M1, M2, and
M3, are shown as purple spheres, and dashed black lines illustrate their likely coordination (interatomic distances
of 2.2 Å).
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important binding determinants. InT. bruceiGCL,mutation of
Thr323 (Thr370 in ScGCL) to an alanine dramatically increased
the apparent Km for ATP (39). Interestingly, the imidazole ring
of His94 moves 1.4 Å toward the ADP molecule and forms
hydrogen bonds with an -phosphate oxygen and the -car-
boxylate of Glu103 (not shown). Three bound Mg2 molecules
provide additional stabilizing interactions as described below.
Three Bound Mg2 Ions Contribute to the Formation and
Binding of the Transition State Analogue—In the ScGCL-BSO
structure, three octahedrally coordinated Mg2 ions are
observed (Fig. 4C). The first metal-binding site, M1, is formed
by the side chain carboxylates of Glu52, Glu96, and Glu103; the
sulfoximine nitrogen; an oxygen of the covalently attached
phosphate group; and an ordered water molecule. The M2 site
is fashioned from the side chains ofGln268, Glu50, andGlu470, as
well as from oxygen atoms from the  phosphate of ADP and
the phosphoryl group of the transition state analogue. The M3
site is in contact with oxygen atoms from each of the three
phosphate groups, the carboxylates of Glu50 and Glu103, and a
bound water molecule. This constellation of Mg2-binding
sites facilitates the binding of ATP and positions the -phos-
phate of ATP for in-line nucleophilic attack by the -carboxy-
late of the glutamate substrate. As mentioned above, Arg472 is
likely a key residue in this initial step of catalysis.
The coordination of these critical Mg2 ions appears to be
highly conserved. A similar arrangement of active site Mg2
ions is observed in the equivalent E. coli GCL structure (40),
despite less than 10% sequence identity between the Group 1
and 2 enzymes. Mutation of glutamate residues 55 and 100 in
T. brucei GCL (equivalent to Glu52 and Glu103 in ScGCL) to
alanine led to a striking loss of enzyme activity, suggesting that
Glu52 and Glu103 are indispensable for catalysis (42). Substitu-
tions at either residue likely result in the loss ofMg2 binding at
theM1 site. Interestingly,mutation ofGlu93 inT. bruceiGCL to
alanine (equivalent to Glu96 in
ScGCL) resulted in an enzyme capa-
ble of ATP hydrolysis. However, the
E93Amutant could not catalyze the
peptide bond formation between
L-glutamate and L-aminobutyrate (a
surrogate for L-cysteine), suggesting
that this glutamate residue may
instead facilitate the nucleophilic
attack of L-cysteine on the -glu-
tamylphosphate intermediate (42).
Identification of the Cysteine-
binding Site of ScGCL—Attempts to
crystallize a pseudo-Michaelis com-
plex have been unsuccessful. In each
case, the electron density for the cys-
teine substrate has been quite poor,
precluding the direct identification of
the cysteine-binding pocket. To over-
come this limitation, the ScGCL-glu-
tathione and ScGCL-BSO structures
were superimposed, and the envi-
ronment surrounding the cysteine
or cysteine mimic was examined
(Fig. 5). The thiol group of glutathione and the S-butyl group of
BSO overlay reasonably well and are located in a hydrophobic
pocket lined by Tyr97, Phe197, Leu200, Met258, Met262, and
Trp445. The cysteinyl amino and carbonyl groups of glutathione
are within hydrogen bond distance of the -carboxylate of
Glu96 and the indole nitrogen of Trp445. These two residues
likely orient the incoming cysteine substrate, and Glu96 may
facilitate the nucleophilic attack of the -amino group of cys-
teine on the -glutamylphosphate, leading to the displacement
of the phosphate group and the formation of the -glutamyl
peptide bond (1–4). In addition, the guanidinium group of
Arg196 may coordinate the -carboxylate of cysteine, similar to
the arrangement seen for binding of the glycine portion of glu-
tathione (Fig. 3). In support of this assertion, mutagenesis stud-
ies of T. bruceiGCL indicated that Arg179 (Arg196 in ScGCL) is
required for efficient binding of the cysteine analogue, L-ami-
nobutyrate (39).
Comparison of the ScGCL-BSO structure with that of E. coli
GCL in complex with the related mechanism-based inhibitor,
(2S)-2-amino-4-[(2S)-2-carboxybutyl-(R)-sulfonimidoyl]bu-
tanoic acid (40), suggests potential differences in cysteine bind-
ing. In E. coli GCL, the cysteine pocket is formed concurrently
with a conformation change in a switch loop (residues 240–
249). As a result, the carboxyl group of the inhibitor cysteine
moiety is positioned to form a hydrogen bond with Tyr300, as
well as Tyr131. In ScGCL there are no significant conforma-
tional changes in the backbone of the enzyme upon inhibitor
binding, and Tyr300 and Tyr131 of the E. coli enzyme appear to
be functionally replaced byTrp445 andArg196. Interestingly, the
cysteine-binding pocket of B. juncea GCL (41) more closely
resembles that of ScGCL. However, both enzyme structures
were determined in complex with BSO, which lacks the func-
tional equivalent of the -carboxylate of the cysteine substrate.
FIGURE 5. Superpositioning of the glutathione and BSO binding sites indicate the location of the cys-
teine-binding site. Bound ADP and BSO are shown in ball and stick representation, and pertinent active site
residues are shown in stick representation in the stereodiagram. Atoms are colored as in Fig. 2, with the
exception of carbon atoms in BSO (colored in magenta). The S-butyl group of BSO and the thiol group of
glutathione occupy a comparable hydrophobic pocket in the ScGCL active site.
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Perhaps additional conformational changes would occur if this
moiety were present.
Implications for Catalysis and Inhibitor Design—The avail-
able biochemical and structural data provide many of the
details of the catalytic mechanism of the enzyme (Fig. 6). Glu-
tamate binds at the base of the enzyme active site with its side
chain carboxylate occupying one of the coordination sites of the
M1 Mg2. The nucleophilicity of the -carboxylate is likely
increased by the adjacent Mg2 as well as the side chain of
Arg472. The addition of Mg2/ATP leads to the formation of
two additional magnesium-binding sites, M2 and M3, which
orient the phosphate groups of ATP, placing the -phosphate
in position for in-line attack by the activated glutamate sub-
strate. This leads to the formation of a -glutamyl phosphate
intermediate, which is tightly anchored in the enzyme active
site, and the eventual displacement of ADP. The incoming cys-
teine nucleophile is potentially activated by the side chain car-
boxylate of Glu96, and the developing negative charge on the
-carboxylate oxygen of the glutamate substrate is stabilized by
the side chain of Arg472. Collapse of the tetrahedral intermedi-
ate leads to the expulsion of the phosphate group and the for-
mation of the-glutamyl peptide bond. Additional biochemical
and mutational studies to examine this proposed mechanism
are ongoing. However, the essential features of catalysis appear
to be conserved in related enzymes such as glutamine synthe-
tase (43, 44), glutathione synthetase (45–47), and homogluta-
thione synthetase (48).
Elucidation of the detailed catalytic mechanism of GCL in
conjunction with the structural studies of the inhibited ScGCL
may lead to improved glutathione biosynthesis inhibitors. The
FIGURE 6. Proposed Catalytic mechanism of ScGCL. The proposed catalytic mechanism depicted is based on available biochemical and structural data for
ScGCL as discussed in the text. Arg472 of ScGCL, the residue proposed to stabilize the anionic transition state, is also shown. Additional biochemical and kinetic
studies will be required to validate the mechanism, particularly with regard to activation of the nucleophilic cysteine.
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alkyl sulfoximine-based inhibitors are excellent transition state
mimics that dramatically reduce enzymatic activity. Examina-
tion of the ScGCL-BSO complex suggests that additional func-
tionalitiesmay be engineered to increase selectivity. ScGCL and
human GCL share 	40% sequence identity, with nearly com-
plete conservation of active site architecture (24), suggesting
that the insights garnered from the study of ScGCL will facili-
tate the development of improved therapeutics that modulate
glutathione production in mammalian systems.
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Supplemental data. 
 
 
 
Supplemental Figure 1.  To examine the mode of inhibition of glutathione, rates for the enzyme-
catalyzed reaction as a function of glutamate concentration were determined in the presence of fixed 
concentrations of glutathione (0, 2.5, and 5.0 mM).  Global analysis of the dependence of rate versus 
substrate concentration indicated that glutathione was a competitive inhibitor with respect to glutamate, 
with an apparent Ki (GSH) of 2.12 ± 0.13 mM. 
	  
	   2	  
 
 
 
 
 
Supplemental Figure 2.  The structure of ScGCL in complex with glutathione was determined by 
molecular replacement using the apo form of ScGCL as a probe.   Shown in the stereodiagram is the 
calculated difference map prior to the inclusion of ligands and solvent in the model.  Positive and negative 
peaks are contoured at 3.0 σ and shown in blue and red respectively.  The final ScGCL-GSH model 
corresponding to this region of the map is shown in stick representation with carbon atoms colored in 
green, oxygen in red, nitrogen in blue, and sulfur in yellow.  Glutathione is shown in ball and stick 
representation with carbon atoms colored grey. 
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Supplemental Figure 3.  The structure of ScGCL in complex with phosphorylated BSO and ADP was 
determined by molecular replacement using the apo form of ScGCL as a probe.   Shown in the 
stereodiagram is the calculated difference map prior to the inclusion of ligands and solvent in the model.  
Positive and negative peaks are contoured at 3.0 σ and shown in blue and red respectively.  The final 
ScGCL-BSO model corresponding to this region of the map is shown in stick representation with carbon 
atoms colored in green, oxygen in red, nitrogen in blue, sulfur in yellow, magnesium in magenta, and 
phosphorus in orange.  BSO and ADP are shown in ball and stick representation with carbon atoms 
colored grey. 
	  
